Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base

References

• Castillo JJ, Chavez JC, Hernandez-Ilizaliturri FJ, et al. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015;8:343–354.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao S, Wang J, et al. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. Tumour Biol. 2016;37:3619–3637.
   PubMedGoogle Scholar
• Montes-Moreno S, Montalban C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma. 2012;53:185–194.
   PubMed Web of Science ®Google Scholar
• Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12:569–576.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–2330.
   PubMed Web of Science ®Google Scholar
• Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. JCO. 2009;27:4211–4216.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Said J, Gratzinger D, et al. HHV8/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP workshop report-part. Am J Clin Pathol. 2017;147:171–187.
   PubMedGoogle Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–1412.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–1224.
   PubMed Web of Science ®Google Scholar
• Guillet S, Gerard L, Meignin V, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91:233–237.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Fallah J, Castillo JJ. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer. 2016;122:2689–2697.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017 [Feb 23]. doi: 10.1001/jamaoncol.2016.6905
   Web of Science ®Google Scholar
• Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–690.
   PubMed Web of Science ®Google Scholar
• Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Adv. 2016;1:112–121.
   PubMed Web of Science ®Google Scholar
• Kaplan LD. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematol Am Soc Hematol Educ Program. 2013;2013:103–108.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Survival outcomes of secondary cancers in patients with Waldenstrom macroglobulinemia: an analysis of the SEER database. Am J Hematol. 2015; 90:696–701.
   PubMed Web of Science ®Google Scholar
• Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. College Station (TX): Stata Press; 2011.
   Google Scholar
• Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26:1163–1172.
   PubMed Web of Science ®Google Scholar
• Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. JCO. 2003;21:3948–3954.
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. JCO. 2005;23:4372–4380.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Shum H, Lahijani M, et al. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012;53:2378–2382.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28:1401–1416.
   PubMed Web of Science ®Google Scholar
• Chan TSY, Mak V, Kwong YL. Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. Ann Hematol. 2017;96:1211–1213.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Zuckermann B, Schattner A. Primary effusion lymphoma in the absence of HIV infection-clinical presentation and management. QJM. 2015;108:481–488.
   PubMed Web of Science ®Google Scholar
• Antar A, El Hajj H, Jabbour M, et al. Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature. Blood Cancer J. 2014;4:e190.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Markovic SN, Kalokhe U, et al. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17:1849–1850.
   PubMed Web of Science ®Google Scholar
• Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005;19:473–476.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15:293–299.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047–2053.
   PubMed Web of Science ®Google Scholar
• Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28:843–848.
   PubMed Web of Science ®Google Scholar
• Pan Z, Hu S, Li M, et al. ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature. Am J Surg Pathol. 2017;41:25–38.
   PubMed Web of Science ®Google Scholar
• Werner MT, Zhao C, Zhang Q, et al. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129:823–831.
   PubMed Web of Science ®Google Scholar
• Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kissnase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378.
   PubMedGoogle Scholar
• Wass M, Behlendorf T, Schadlich B, et al. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2014;92:268–270.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–2336.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Farre B, Martinez D, Lopez-Guerra M, et al. HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Mod Pathol. 2017;30:745–760.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014;19:1249–1257.
   PubMed Web of Science ®Google Scholar
• Suneja G, Shiels MS, Angulo R, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32:2344–2350.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991–999.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-cell Lymphomas. Version 3.2017 – March 27, 2017.
   Google Scholar
• Castillo JJ, Reagan JL, Sikov WM, et al. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352–355.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122:1233–1242.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Laurent C, Fabiani B, Do C, et al. Immune-checkpoint expression in Epstein–Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016;101:976–984.
   PubMed Web of Science ®Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14:203–220.
   PubMed Web of Science ®Google Scholar
• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. JCO. 2017;35:2008.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Kho ME, Friedberg JW, et al. Comparison of referring and final pathology for patients with non-Hodgkin’s lymphoma in the National Comprehensive Cancer Network. JCO. 2008;26:5107–5112.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Stewart AK, et al. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. JCO. 2009;27:4177–4181.
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor TH, Im T, et al. How valid is using cancer registries’ data to identify acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma? Cancer Causes Control. 2007;18:135–142.
   PubMed Web of Science ®Google Scholar